Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACRS Aclaris Therapeutics

Post-Mkt 05-27 16:23:09 EDT

4.58

+0.07

+1.55%

盘后4.58

+0.000.00%

16:10 EDT

High4.69	Low4.50	Vol682.63K
Open4.51	D1 Closing4.51	Amplitude4.10%
Mkt Cap641.20M	Tradable Cap441.59M	Total Shares140.00M
T/O3.13M	T/O Rate0.71%	Tradable Shares96.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ACRS","market":"US","secType":"STK","nameCN":"Aclaris Therapeutics","latestPrice":4.58,"timestamp":1779912000000,"preClose":4.51,"halted":0,"volume":682632,"hourTrading":{"tag":"盘后","latestPrice":4.58,"preClose":4.58,"latestTime":"16:10 EDT","volume":13741,"amount":62933.78,"timestamp":1779912605242,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01552106430155217,"floatShares":96417099,"shares":140000000,"eps":-0.561022,"marketStatus":"Post-Mkt","change":0.07,"latestTime":"05-27 16:23:09 EDT","open":4.51,"high":4.685,"low":4.5,"amount":3134802,"amplitude":0.04102,"askPrice":5,"askSize":40,"bidPrice":4.34,"bidSize":53,"shortable":3,"etf":0,"ttmEps":-0.561022,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1779926400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1444190400000,"exchange":"NASDAQ","adjPreClose":4.51,"postHourTrading":{"tag":"盘后","latestPrice":4.58,"preClose":4.58,"latestTime":"16:10 EDT","volume":13741,"amount":62933.78,"timestamp":1779912605242,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.849833,"impliedVol":0.77,"impliedVolPercentile":0.1195},"requestUrl":"/m/hq/s/ACRS/tweets","defaultTab":"tweets","newsList":[{"id":"2634286125","title":"Aclaris Therapeutics (ACRS) Gets a Buy from Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2634286125","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634286125?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:55","pubTimestamp":1778500532,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Biren Amin maintained a Buy rating on Aclaris Therapeutics today and set a price target of $11.00. According to TipRanks, Ami...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/aclaris-therapeutics-acrs-gets-a-buy-from-piper-sandler-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/aclaris-therapeutics-acrs-gets-a-buy-from-piper-sandler-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634128618","title":"Guggenheim Keeps Their Buy Rating on Aclaris Therapeutics (ACRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634128618","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634128618?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:52","pubTimestamp":1778500377,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Seamus Fernandez reiterated a Buy rating on Aclaris Therapeutics today and set a price target of $12.00. According to TipRanks, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-aclaris-therapeutics-acrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-aclaris-therapeutics-acrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634020034","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2634020034","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634020034?lang=en_us&edition=fundamental","pubTime":"2026-05-11 18:00","pubTimestamp":1778493600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·ATL Braves C                                   1Q      (.78)   8:00 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLLS","APC","ATRO","CVRX","CGBD","ASTS","ANDG","AEYE","CERT","ACRS","ABCL","DCGO","AMTM","CRCL","CEG","CLSK","ACH","AGNT","ALGS","CDRE","ARVN","ACET","BGS","BLNK","BTAI","CINT","ABOS","ALLT","BCSF","COOK","BCAX","ARMK","AMBQ","B","CBLL","BATRA","APEI","ACHV","BIOA","BODI","BRCB","BETA","AIP","ASRT","BATRK","ACXP","CEVA","CHRS","BALY","ACM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634475355","title":"Analysts Offer Insights on Healthcare Companies: Medline (MDLN), Aclaris Therapeutics (ACRS) and Alkermes (ALKS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634475355","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634475355?lang=en_us&edition=fundamental","pubTime":"2026-05-11 10:41","pubTimestamp":1778467285,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Medline (MDLN), Aclaris Therapeutics (ACRS) and Alkermes (ALKS). ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-medline-mdln-aclaris-therapeutics-acrs-and-alkermes-alks-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-medline-mdln-aclaris-therapeutics-acrs-and-alkermes-alks-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALKS","LU0029874061.USD","BK4137","BK4588","LU0128526141.USD","ACRS","BK4581","HCSG","MDLN","XLV","BK4198","BK4139","BK4585","BK4007","XBI","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633560804","title":"Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2633560804","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633560804?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:30","pubTimestamp":1778243400,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., May  08, 2026  -- Aclaris Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday May 14, 2026, at 9:35 AM PT, Aclaris’ President and Chief Operating Officer Dr. Hugh Davis will provide a corporate presentation during the 2026 Bank of America Healthcare Conference in Las Vegas, NV. A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days. About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information,","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/08/3291054/37216/en/Aclaris-Therapeutics-to-Participate-in-the-2026-Bank-of-America-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAC","LU0208291251.USD","LU1883839398.USD","LU1074936037.SGD","BK4534","LU0321505439.SGD","LU1201861165.SGD","IE00BLSP4239.USD","ACRS","IE00B19Z3B42.SGD","IE00BBT3K403.USD","LU0029874061.USD","LU0052756011.USD","LU1791807156.HKD","BK4582","IE00BFXG1179.USD","BK4581","LU2129689605.HKD","LU0203347892.USD","LU0320765646.SGD","LU0648001328.SGD","BK4007","LU1267930227.SGD","LU0130103400.USD","LU0640476718.USD","LU0683600562.USD","LU0098860793.USD","LU0070302665.USD","LU1201861249.SGD","IE0001KFT4U8.USD","IE00BLSP4452.SGD","LU1496350502.SGD","LU0130517989.USD","LU2129689514.USD","LU0306807586.USD","LU0128526141.USD","IE0002270589.USD","BK4504","IE00B19Z3581.USD","IE00B7SZLL34.SGD","LU1880398471.USD","LABU","LU0310800965.SGD","LU1280957306.USD","LU1668664300.SGD","XLV","LU1894683348.USD","XBI","PGF","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633123414","title":"Aclaris Therapeutics (ACRS) Gets a Buy from Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2633123414","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633123414?lang=en_us&edition=fundamental","pubTime":"2026-05-07 21:55","pubTimestamp":1778162145,"startTime":"0","endTime":"0","summary":"Craig-Hallum analyst Adam Vogel maintained a Buy rating on Aclaris Therapeutics today and set a price target of $10.00. Vogel covers the Healthcare...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/aclaris-therapeutics-acrs-gets-a-buy-from-craig-hallum-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/aclaris-therapeutics-acrs-gets-a-buy-from-craig-hallum-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","LABU","BK4007","XBI","BK4588","ACRS","BK4585","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633412383","title":"Aclaris Therapeutics reports Q1 EPS (15c), consensus (16c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633412383","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633412383?lang=en_us&edition=fundamental","pubTime":"2026-05-07 21:36","pubTimestamp":1778161015,"startTime":"0","endTime":"0","summary":"Reports Q1 revenue $2M, consensus $1.32M. “Since the start of 2026, we have made great progress toward our goal of developing best-in-class compoun...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-reports-q1-eps-15c-consensus-16c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-reports-q1-eps-15c-consensus-16c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633128373","title":"Aclaris Therapeutics Q1 EPS $(0.15), Inline, Sales $1.996M Beat $1.322M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633128373","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633128373?lang=en_us&edition=fundamental","pubTime":"2026-05-07 21:23","pubTimestamp":1778160220,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 25 percent decrease over losses of $(0.12) per share from the same period last year. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52366820/aclaris-therapeutics-q1-eps-0-15-inline-sales-1-996m-beat-1-322m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633054140","title":"Aclaris Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633054140","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633054140?lang=en_us&edition=fundamental","pubTime":"2026-05-07 21:18","pubTimestamp":1778159917,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryAclaris Therapeutics Inc ACRS.OQ reported a quarterly adjusted loss of 15 cents per share for the quarter ende","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL8N41K1O9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145989","title":"Aclaris Therapeutics Q1 net loss widens on higher R&D spending","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145989","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145989?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:06","pubTimestamp":1778152015,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics Q1 net loss widens on higher R&D spendingOverviewUS biopharma firm's Q1 revenue rose and beat analyst expectationsQ1 adjusted EPS beat consensusNet loss widened and missed analyst","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL1N41K0KN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0046","BK4007","BK0012","300485","BK0239","ACRS","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633114364","title":"BRIEF-Aclaris Therapeutics Q1 EPS USD -0.15 Vs. IBES Estimate USD -0.16","url":"https://stock-news.laohu8.com/highlight/detail?id=2633114364","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633114364?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:59","pubTimestamp":1778151585,"startTime":"0","endTime":"0","summary":"BRIEF-Aclaris Therapeutics Q1 EPS USD -0.15 Vs. IBES Estimate USD -0.16\n\n\nMay 07 (Reuters) - Aclaris Therapeutics Q1 revenue USD 1.996 million vs. IBES estimate USD 1.32 million.\n\nQ1 net income USD -19.824 million vs. IBES estimate USD -19.6 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLX1A3634:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145354","title":"Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145354","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145354?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:59","pubTimestamp":1778151540,"startTime":"0","endTime":"0","summary":"- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Exceed Aclaris’ Target Profile, Validating Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - - Unique Dual ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289773/37216/en/Aclaris-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-and-Clinical-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1169590202.USD","BSA","BK4132","BK4023","BK4218","PD","BK4181","LU1169589451.USD","PK","AD","ACRS","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633858928","title":"Aclaris Therapeutics Is Maintained at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2633858928","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633858928?lang=en_us&edition=fundamental","pubTime":"2026-05-06 02:20","pubTimestamp":1778005200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACRS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 05, 2026 14:20 ET (18:20 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633943141","title":"Aclaris Therapeutics Initiated at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2633943141","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633943141?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:55","pubTimestamp":1777985700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACRS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 05, 2026 08:55 ET (12:55 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633914974","title":"Aclaris Therapeutics price target raised to $11 from $7 at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2633914974","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633914974?lang=en_us&edition=fundamental","pubTime":"2026-05-05 18:58","pubTimestamp":1777978723,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Biren Amin raised the firm’s price target on Aclaris Therapeutics (ACRS) to $11 from $7 and keeps an Overweight rating on the...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-price-target-raised-to-11-from-7-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-price-target-raised-to-11-from-7-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633969642","title":"Aclaris Therapeutics initiated with a Buy at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2633969642","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633969642?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:40","pubTimestamp":1777927203,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Seamus Fernandez initiated coverage of Aclaris Therapeutics (ACRS) with a Buy rating and $12 price target Published first on The...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-initiated-with-a-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-initiated-with-a-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633963927","title":"Damora Therapeutics names Brian Burkavage principal financial officer, accounting officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2633963927","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633963927?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:01","pubTimestamp":1777924862,"startTime":"0","endTime":"0","summary":"Damora Therapeutics set May 1, 2026 as effective date for CFO Lori Firmani to step down.Senior Vice President, Finance Brian Burkavage will become principal financial officer and principal accounting officer at that time.Burkavage previously served as senior vice president, finance and chief accounting officer at IO Biotech from November 2021 to December 2025.Earlier roles included controller at Passage Bio, director of financial planning and analysis at Aclaris Therapeutics, and 11 years at Ernst & Young in audit.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDLbYN4kT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DMRA","IOBTQ","BK4007","PASG","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632956451","title":"Aclaris Therapeutics Inc  expected to post a loss of 16 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2632956451","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632956451?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:37","pubTimestamp":1777901827,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics Inc  expected to post a loss of16cents a share - Earnings Preview Aclaris Therapeutics Inc ACRS.OQ ACRS.O is expected to  show a fall in quarterly revenue when it reports  results","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL8N41H1BT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632933604","title":"JTL Industries Wins ACRS Nod, Tightens Grip on Global Structural Steel Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2632933604","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632933604?lang=en_us&edition=fundamental","pubTime":"2026-05-04 14:12","pubTimestamp":1777875174,"startTime":"0","endTime":"0","summary":"JTL Industries Limited ( ($IN:JTLIND) ) has issued an update. JTL Industries has secured Product Conformity Certification from the Australasian Cer...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/jtl-industries-wins-acrs-nod-tightens-grip-on-global-structural-steel-markets?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/jtl-industries-wins-acrs-nod-tightens-grip-on-global-structural-steel-markets?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ACRS","BK4535","PICK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631413535","title":"Aclaris Therapeutics Is Maintained at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2631413535","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631413535?lang=en_us&edition=fundamental","pubTime":"2026-04-30 00:13","pubTimestamp":1777479180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACRS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 29, 2026 12:13 ET (16:13 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aclaristx.com","stockEarnings":[{"period":"1week","weight":0.0135},{"period":"1month","weight":0.0488},{"period":"3month","weight":0.3625},{"period":"6month","weight":0.566},{"period":"1year","weight":2.5794},{"period":"ytd","weight":0.4983}],"compareEarnings":[{"period":"1week","weight":0.023},{"period":"1month","weight":0.0513},{"period":"3month","weight":0.0829},{"period":"6month","weight":0.1043},{"period":"1year","weight":0.2961},{"period":"ytd","weight":0.1007}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.145543},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.038718},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.021975},{"month":4,"riseRate":0.454545,"avgChangeRate":0.005147},{"month":5,"riseRate":0.545455,"avgChangeRate":-0.035777},{"month":6,"riseRate":0.6,"avgChangeRate":-0.004956},{"month":7,"riseRate":0.6,"avgChangeRate":0.009999},{"month":8,"riseRate":0.5,"avgChangeRate":-0.019617},{"month":9,"riseRate":0.4,"avgChangeRate":0.026634},{"month":10,"riseRate":0.4,"avgChangeRate":0.132278},{"month":11,"riseRate":0.363636,"avgChangeRate":0.075295},{"month":12,"riseRate":0.727273,"avgChangeRate":0.092435}],"exchange":"NASDAQ","name":"Aclaris Therapeutics","nameEN":"Aclaris Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aclaris Therapeutics(ACRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aclaris Therapeutics,ACRS,Aclaris Therapeutics股票,Aclaris Therapeutics股票老虎,Aclaris Therapeutics股票老虎国际,Aclaris Therapeutics行情,Aclaris Therapeutics股票行情,Aclaris Therapeutics股价,Aclaris Therapeutics股市,Aclaris Therapeutics股票价格,Aclaris Therapeutics股票交易,Aclaris Therapeutics股票购买,Aclaris Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aclaris Therapeutics(ACRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}